Compare BridgeBio Pharma Inc (BBIO) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs OneSpan Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while OneSpan Inc trades at $16.25 (market cap $603.27M). The key difference: BridgeBio Pharma Inc is far larger — about 27.5× OneSpan Inc's market cap, and OneSpan Inc pays a 3.18% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | OSPN | |
|---|---|---|
Market Cap | $16.61B | $603.27M |
Sector | Health | Technology |
52-Week High | $90.17 | $16.78 |
52-Week Low | $47.29 | $10.15 |
Enterprise Value | $18.16B | $572.35M |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
OneSpan (OSPN) trades at $16.78, up 3.33% today, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a P/E of 9.25, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 revenue growth and raised full-year guidance, reflecting positive business momentum.
The outlook is positive, driven by earnings strength and strategic initiatives, but risks include competitive pressures and potential margin compression. With a consensus price target of $17.00 and 67% buy ratings, Wall Street sees modest upside from current levels amid overall solid financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
